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Background-—Natriuretic peptides are recognized as important predictors of cardiovascular events in patients with heart failure,
but less is known about their prognostic importance in patients with acute coronary syndrome. We sought to determine whether
B-type natriuretic peptide (BNP) and N-terminal prohormone B-type natriuretic peptide (NT-proBNP) could enhance risk prediction
of a broad range of cardiovascular outcomes in patients with acute coronary syndrome and type 2 diabetes mellitus.
Methods and Results-—Patients with a recent acute coronary syndrome and type 2 diabetes mellitus were prospectively enrolled
in the ELIXA trial (n=5525, follow-up time 26 months). Best risk models were constructed from relevant baseline variables with and
without BNP/NT-proBNP. C statistics, Net Reclassiﬁcation Index, and Integrated Discrimination Index were analyzed to estimate
the value of adding BNP or NT-proBNP to best risk models. Overall, BNP and NT-proBNP were the most important predictors of all
outcomes examined, irrespective of history of heart failure or any prior cardiovascular disease. BNP signiﬁcantly improved C
statistics when added to risk models for each outcome examined, the strongest increments being in death (0.77–0.82, P<0.001),
cardiovascular death (0.77–0.83, P<0.001), and heart failure (0.84–0.87, P<0.001). BNP or NT-proBNP alone predicted death as
well as all other variables combined (0.77 versus 0.77).
Conclusions-—In patients with a recent acute coronary syndrome and type 2 diabetes mellitus, BNP and NT-proBNP were powerful
predictors of cardiovascular outcomes beyond heart failure and death, ie, were also predictive of MI and stroke. Natriuretic
peptides added as much predictive information about death as all other conventional variables combined.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01147250. ( J Am Heart Assoc. 2017;6:
e004743. DOI: 10.1161/JAHA.116.004743.)
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P atients admitted with an acute coronary syndrome (ACS)are at increased risk of subsequent cardiovascular
events, especially those with type 2 diabetes mellitus,1,2
who constitute 30% of all ACS patients.3 Determining the
predictors of death, myocardial infarction (MI), heart failure
(HF), and stroke among these patients is important as it
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assists in identifying the individuals at highest risk of these
various outcomes. These individuals should be the focus of
the most intensive secondary preventive strategies. In the
same way, risk stratiﬁcation may help motivate both patients
and clinicians in secondary preventive efforts. Lastly, predic-
tive models can be used to select the highest risk individuals
for trials of new secondary preventive therapies.
B-type natriuretic peptide (BNP) and N-terminal prohor-
mone B-type natriuretic peptide (NT-proBNP) levels are well
established predictors of HF hospitalization and mortality in
patients with HF.4–7 However, as the incidences of outcomes
differ between patients with HF8 and patients with a recent
ACS9 in a stable phase, it is less established how natriuretic
peptides are associated with cardiovascular outcomes,
especially subsequent MI and stroke, in the latter popula-
tion.3,10–14 Concentrations of natriuretic peptides may be
affected by both asymptomatic myocardial ischemia15,16 and
atrial ﬁbrillation,17,18 which could make BNP and NT-proBNP
relevant as predictors of MI and stroke. However, trials
investigating patients at high risk of atherosclerotic events
have found conﬂicting results regarding both the predictive
ability of natriuretic peptides and cardiovascular outcomes—
including MI and stroke—as well as the predictive strength of
BNP versus NT-proBNP.19–22
We wanted to expand knowledge of these natriuretic
peptides as predictors of death, cardiovascular death,
myocardial infarction, heart failure, and stroke in patients
with a recent coronary event and type 2 diabetes mellitus
enrolled in the Evaluation of Lixisenatide in Acute Coronary
Syndrome trial (ELIXA, NCT01147250). Data from the ELIXA
trial allowed us to compare the predictive strength of baseline
BNP and NT-proBNP in a high risk ACS patient cohort with
type 2 diabetes mellitus. In addition, prospective ascertain-
ment during a reasonable follow-up period, and adjudication
of a variety of cardiovascular events, ensured detailed and
validated data for analyses.
Methods
The ELIXA trial (Evaluation of Lixisenatide in Acute Coronary
Syndrome) trial included 6068 patients with type 2 diabetes
mellitus and an acute coronary event within 180 days from
randomization (index event).23 The study was approved by
the appropriate national and institutional regulatory and
ethics boards, and all subjects gave informed consent. The
objective of the ELIXA trial was to assess the safety and
efﬁcacy of lixisenatide, a glucagon-like peptide-1 receptor
agonist, on cardiovascular morbidity and mortality. Details of
the trial design and the demographic and clinical character-
istics of the included patients have been reported previ-
ously.24 In summary, patients were included in this
randomized, double-blind, placebo-controlled, parallel-group
study, between 2010 and 2013, from 49 countries, and
followed for a median of 25 months. Key exclusion criteria
were percutaneous coronary intervention within 15 days of
screening or planned percutaneous coronary intervention
within 90 days after screening, coronary artery bypass graft
treatment at the index event, an estimated glomerular
ﬁltration rate of less than 30 mL/min per 1.73 m2 of body-
surface area, a glycated hemoglobin level of less than 5.5%
or more than 11.0%, or an inability to provide written
informed consent. Patients were randomized to subcuta-
neous injections of either lixisenatide (maximum 20 lg daily)
or placebo (volume matched) in addition to locally deter-
mined standards of care. The ELIXA trial showed that
lixisenatide had a neutral effect with regard to the occur-
rence of the primary outcome (cardiovascular death, MI,
stroke, or hospitalization for unstable angina) and HF
hospitalization.23
Covariates and Outcomes
All data pertaining to baseline variables including demograph-
ics, anthropometrics, cardiovascular risk factors, and prior
medical history were obtained at the time of randomization in
the study. All events were reported to a centralized and
independent adjudication committee who classiﬁed events
according to prespeciﬁed deﬁnitions.24 Data on adjudicated
time-to-event for outcomes of all-cause death (death),
cardiovascular death (cardiovascular death), heart failure
hospitalization (HF), fatal and nonfatal myocardial infarction
(MI), and fatal and nonfatal stroke (stroke) were used for
analyses.
BNP and NT-proBNP sampling was carried out at baseline.
Samples were collected and analyzed at a core laboratory
(Covance Central Laboratory Services, Meyrin, Switzerland).
The Triage BNP assay was used to analyze BNP. The intra-
assay coefﬁcient of variation was 1.1% to 3.1%. The interassay
coefﬁcient of variation was 1.8% to 6.6%. The Immulite NT-
proBNP assay was used to analyze NT-proBNP. The intra-
assay coefﬁcient of variation was 2.3% to 5.4%. The interassay
coefﬁcient of variation was 4.0% to 6.4%. BNP and NT-proBNP
samples from 5925 patients (98%) were obtained.
Statistical Analyses
Baseline characteristics shown in Table 1 were selected for
best risk models. Patients without data on all these relevant
variables, including BNP and NT-proBNP measurements, were
excluded (n=543, 9%). The distributions of baseline BNP,
NT-proBNP, and C-reactive protein were found to be right-
skewed and were therefore log-transformed prior to analysis.
Continuous variables were included in the models unless
there was clear evidence of nonlinearity.
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Table 1. Characteristics of All Included Patients
No Cardiovascular Events (n=4626) Cardiovascular Events (n=899) P Value
Randomized to lixisenatide 2327 (50.3%) 449 (49.9%) 0.84
Age, y 59.79.5 63.39.7 <0.001
Male (%) 3238 (70.0%) 627 (69.7%) 0.88
BMI, kg/m2 30.05.6 30.36.1 0.24
Race <0.001
Asian 648 (14.0%) 82 (9.1%)
Black 14 (3.1%) 47 (5.2%)
Other 385 (8.3%) 86 (9.6%)
White 3451 (74.6%) 684 (76.1%)
Ethnicity—Hispanic 1396 (30.2%) 250 (27.8%) 0.16
Region <0.001
Africa/Near East 215 (4.6%) 54 (6.0%)
Asia Pacific 597 (12.9%) 72 (8.0%)
Eastern Europe 1172 (25.3%) 241 (26.8%)
North America 563 (12.2%) 153 (17.0%)
South and Centr. America 1551 (33.5%) 273 (30.4%)
Western Europe 528 (11.4%) 106 (11.8%)
Systolic blood pressure, mm Hg 12917 13119 0.86
Diastolic blood pressure, mm Hg 7710 7711 0.18
Heart rate, bpm 7010 7111 0.001
Current smoker 511 (11.0%) 117 (13.0%) 0.09
Former smoker 2113 (45.7%) 409 (45.5%) 0.92
Medical history
MI 918 (19.8%) 340 (37.7%) <0.001
HF 905 (19.5%) 330 (36.7%) <0.001
Atrial fibrillation/flutter 240 (5.2%) 121 (13.5%) <0.001
PAD 271 (5.9%) 142 (15.8%) <0.001
TIA 83 (1.8%) 44 (4.9%) <0.001
Ventricular tachycardia 57 (1.2%) 17 (1.9%) 0.12
Stroke 201 (4.3%) 91 (10.1%) <0.001
CABG 309 (6.7%) 151 (16.8%) <0.001
Implanted pacemaker 102 (2.2%) 41 (4.6%) <0.001
Carotid disease 87 (1.9%) 52 (5.8%) <0.001
Hypertension 3449 (74.6%) 761 (84.6%) <0.001
Index event <0.001
STEMI 2146 (46.4%) 297 (33.0%)
NSTEMI 1702 (36.8%) 432 (48.1%)
Unstable angina pectoris 778 (16.8%) 170 (18.9%)
PCI at index event 2943 (63.6%) 463 (51.5%) <0.001
Insulin-treated 1699 (36.7%) 460 (51.2%) <0.001
Duration of diabetes mellitus, y 8.87.9 11.99.5 <0.001
Retinopathy 452 (9.8%) 139 (15.5%) <0.001
Continued
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Cox proportional hazard modeling was used to create best
risk models without BNP or NT-proBNP using forward
selection with a cut-off value of 0.05. Separate base risk
models were created for the following outcomes; death,
cardiovascular death, fatal or nonfatal MI, fatal or nonfatal HF
hospitalization, as well as fatal or nonfatal stroke. The
variables selected were ordered according to their v2 value
and sorted in descending order for each outcome. The
predictive ability of base risk models were assessed using
Harrell’s C statistics. Selected 30-day models were made for
comparison with previous studies. Using the selected vari-
ables from the base model, comparison between the predic-
tive ability of the base model compared to the base model
with log2BNP/log2NT-proBNP was assessed for all outcomes.
Changes in C statistics, Net Reclassiﬁcation Index (NRI), and
Integrated Discrimination Index (IDI) were estimated to
evaluate the incremental value of adding BNP or NT-proBNP
to best risk models using a set time of 2 years comparable to
the average follow-up time (somersd package, STATA 13.
survIDINRI package, R 2.3.2).
Identiﬁcation of baseline variables independently associ-
ated with BNP/NT-proBNP were obtained using forward
selection regression models with P<0.001 as a cut-off. The
5 variables with the highest v2 value were listed along with
the r2 values.
To identify the most signiﬁcant predictive threshold of
BNP/NT-proBNP values, we divided the continuous BNP/
NT-proBNP concentrations into arbitrary threshold concen-
trations (ie, 35, 100, 125, 200, 300. . .1000, 2000, 5000).
Then using HF hospitalization as an outcome, a fully
adjusted Cox model with forward selection identiﬁed the
BNP threshold concentration that most signiﬁcantly sepa-
rated patients into a lower versus a higher risk group. A
univariate approach was also carried out using receiver
operating characteristic analysis (SENSPEC package, STATA
13) with binary outcome of HF hospitalization to determine
the optimal cut-off value with respect to Youden index (ie,
sensitivity+speciﬁcity1). Interaction analyses between
natriuretic peptides and timing of the baseline sample in
temporal relation to the index ACS event for outcome of
death was also performed, as was interaction between
natriuretic peptides and type of ACS index event (ST-
elevation MI [STEMI], Non-ST elevation MI [NSTEMI],
Unstable Angina Pectoris [UAP]).
To assess whether the relationship between baseline BNP/
NT-proBNP and hazard was linear, fully adjusted Cox spline
models for each outcome with transformed BNP/NT-proBNP
were analyzed. Concentrations below 35 pg/mL (BNP) or
125 pg/mL (NT-proBNP) were considered normal, as these
concentrations are commonly referenced as diagnostic
Table 1. Continued
No Cardiovascular Events (n=4626) Cardiovascular Events (n=899) P Value
Neuropathy 714 (15.4%) 205 (22.8%) <0.001
Asthma 114 (2.5%) 40 (4.4%) <0.001
COPD 173 (3.7%) 76 (8.5%) <0.001
HbA1c, % 7.61.3 7.91.3 <0.001
HDL, mg/dL 4311 4311 0.65
LDL, mg/dL 7734 8339 <0.001
eGFR, mL/min per 1.73 m2 77.521.1 68.120.6 <0.001
Albuminuria <0.001
Normoalbuminuria 3558 (76.9%) 544 (60.5%)
Microalbuminuria 829 (17.9%) 234 (26.0%)
Macroalbuminuria 239 (5.2%) 121 (13.5%)
Hemoglobin, g/dL 13.81.4 13.51.5 <0.001
Na, mmol/L 140.42.9 140.33.1 0.75
Albumin, g/dL 4.10.3 3.90.4 <0.001
CRP, mg/dL 2.0 (1.9–2.0) 2.7 (2.4–2.9) <0.001
BNP, pg/mL 95 (92–98) 198 (184–213) <0.001
NT-proBNP, pg/mL 285 (274–295) 703 (644–766) <0.001
BMI indicates body mass index; bpm, beats per minute; BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CRP, C-
reactive protein; eGFR, estimated glomerular ﬁltration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoproteins; HF, heart failure; LDL, low-density lipoproteins; MI, myocardial
infarction; NSTEMI, non-ST elevation myocardial infarction; NT-proBNP, N-terminal prohormone B-type natriuretic peptide; PAD, peripheral artery disease; PCI, percutaneous coronary
intervention; STEMI, ST elevation myocardial infarction; TIA, transient ischemic attack.
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thresholds for excluding HF in patients presenting in a
nonacute manner.25 Hence, the risk of death in patients with
these levels were used as references. Both unadjusted and
adjusted models were used to conﬁrm ﬁndings. Risk model-
ing, including interaction analyses (history of HF and
log2BNP/log2NT-proBNP), discriminatory statistics, and Cox
spline models were also analyzed in patients stratiﬁed
according to medical history of HF for BNP.
All BNP/NT-proBNP values were summarized as geometric
mean95% CI. A signiﬁcance level of 0.05 was considered
statistically signiﬁcant.
Results
Baseline Characteristics
Our study included 5525 patients comprising 91% of the
included patients in the ELIXA trial. The median follow-up time
was 26 months. In our population, 4626 (84%) patients did
not experience any cardiovascular event conﬁrmed by adju-
dication. Baseline characteristics of patients with or without a
cardiovascular event are listed in Table 1 (Baseline charac-
teristics according BNP quartiles and as linear covariates are
listed in Tables S1 and S2). Compared with patients not
experiencing a cardiovascular event, those that did were in
general older and more burdened with comorbidity, and were
more likely to have micro- or macroalbuminuria, and a lower
estimated glomerular ﬁltration rate. Blood pressure was
similar in both groups. Baseline BNP and NT-proBNP were
elevated in those subsequently experiencing any cardiovas-
cular event.
Predictive Variables
In separate models, BNP and NT-proBNP were the most
signiﬁcant predictors for each of death from any cause, death
from a cardiovascular cause, HF, and stroke among the
studied variables. The natriuretic peptides were the second
most signiﬁcant predictors for MI (Tables 2 and 3). Apart from
BNP/NT-proBNP, the 14 other variables that conferred the
greatest information were the following: Prior MI, body mass
index, NSTEMI (index event), heart rate (HR), glycated
hemoglobin, percutaneous coronary intervention at the index
event (percutaneous coronary intervention), cerebrovascular
disease (prior stroke/transient ischemic attack), atrial ﬁbril-
lation, prior HF, sodium concentration, macroalbuminuria,
peripheral artery disease (PAD), age, and LDL concentration.
Fifteen and 16 variables were independently associated with
concentrations of BNP/NT-proBNP at the a=0.001 level and
accounted for 26% and 34% of patient-level variability,
respectively. The 5 strongest associated variables are listed
in Tables S3 through S5. Ta
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Enhanced Prediction With BNP and NT-proBNP
To estimate the predictive strength of BNP alone, C statistics
were compared between base models without BNP versus
BNP alone. This showed that the discriminatory ability of base
models without BNP versus BNP was similar in outcomes of
death (Harrell’s C statistics: 0.77 both models [0–30 days:
0.82 versus 0.88, P=0.26]) and in cardiovascular death
(Harrell’s C statistics: 0.77 versus 0.79, P=0.17).
In contrast, BNP was signiﬁcantly less discriminatory
compared with best risk models without BNP for the
outcomes of MI (Harrell’s C statistics: 0.71 versus 0.62), HF
(Harrell’s C statistics: 0.84 versus 0.77) and stroke (Harrell’s
C statistics: 0.75 versus 0.67) (all P≤0.01). Similar estimates
and trends were evident for NT-proBNP.
The strength of BNP and NT-proBNP as contributors to risk
prediction translated into augmented predictive ability of risk
models for all outcomes, as summarized in the increases in C
statistics, NRI, and Integrated Discrimination Index (Table 4).
Although BNP and NT-proBNP did not increase the C statistics
for the risk model for stroke, both peptides improved NRI
signiﬁcantly.
BNP and NT-proBNP were the most predictive variables in
risk models of type of cardiovascular death; however, when
added to best risk models, BNP and NT-proBNP only
signiﬁcantly improved the predictive ability (Harrel’s C statis-
tics) in outcomes of fatal HF and sudden death; fatal HF
(n=39) (Base model: 0.850, BNP: +0.085, NT-proBNP: +0.086,
both P<0.001), and sudden death (n=116) (Base model:
0.773, BNP: +0.024, NT-proBNP: +0.037, P=0.20 and 0.046,
respectively), but not in outcome of fatal MI (n=52) (Base
model: 0.827, BNP: +0.025, NT-proBNP: +0.016, P=0.24 and
0.37, respectively).
In univariate analysis, a BNP concentration of 228 pg/mL
best separated patients into a lower versus higher group at
risk of subsequent HF (sensitivity: 0.62, speciﬁcity: 0.77,
Youden index: 0.39), with a corresponding threshold for NT-
proBNP of 751 pg/mL (sensitivity: 0.67, speciﬁcity: 0.74,
Youden index: 0.41). In adjusted Cox models, a BNP
concentration of 500 pg/mL provided the most signiﬁcant
threshold by which to further identify patients at lower versus
higher risk of subsequent HF (HR 3.0 [2.1–4.1], P<0.0001),
with a corresponding threshold for NT-proBNP of 700 pg/mL
(HR 2.5 [1.7–3.5], P<0.0001).
Predictive Strength of BNP Compared to NT-
proBNP
There was no signiﬁcant increase in C statistics when BNP
was included in the best risk models compared to NT-proBNP
in outcomes of death +0.002 (P=0.55), cardiovascular death
+0.0002 (P=0.97), MI +0.002 (P=0.50), HF +0.0001 (P=0.98), Ta
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stroke +0.002 (P=0.88). The comparable estimates were
confounded by a signiﬁcant correlation between BNP and NT-
proBNP (Spearman’s rho 0.86, P<0.0001).
Subgroup and Sensitivity Analyses
In our population, 22% had a history of HF. As sensitivity
analysis, patients were stratiﬁed according to history of HF at
baseline to provide ranking and estimates of important risk
factors, although there was no signiﬁcant interaction with
natriuretic peptides and history of HF (death; BNP, P=0.57.
NT-proBNP, P=0.21, Figure S1). BNP was the strongest
prognostic variable for all outcomes examined in both groups
(prior HF; Tables S6 through S8). Sensitivity analysis was
also done in the subset of patients (52%) without any prior
cardiovascular disease at baseline (HF, atrial ﬁbrillation,
peripheral artery disease, transient ischemic attack/stroke,
ventricular tachycardia, coronary artery bypass graft or MI
apart from index event). The same trends were also evident in
this subset (Tables S9 and S10).
Analysis in the subset of patients that had information
on left ventricular ejection fraction present at their index
ACS was performed (n=3390). Left ventricular ejection
fraction was not among the 3 most signiﬁcant predictors
across all outcomes when added to the variable list. The
predictive ability of BNP and NT-proBNP was comparable in
this subset compared to the entire cohort (Tables S11
through S13).
The timing of the sampling in relation to the index ACS
event did not affect the risk estimates for death for BNP
(P=0.63) or NT-proBNP (P=0.46), nor did the type of ACS
(BNP, P=0.30; NT-proBNP, P=0.32).
There was no signiﬁcant interaction between sex and
concentrations of BNP (P=0.17) or NT-proBNP (P=0.58) when
tested in a fully adjusted model.
Discussion
Our goal was to examine the strength of BNP and NT-proBNP
in predicting a range of cardiovascular outcomes in high risk
ACS patients with type 2 diabetes mellitus. We found that
baseline levels of these natriuretic peptides were elevated in
patients with a subsequent cardiovascular event during
follow-up compared with those not having an event. The
levels of natriuretic peptides most likely reﬂect that all
patients recently suffered a coronary event and on average
had a high comorbid burden.
The signiﬁcance of elevated natriuretic peptides was
reiterated when BNP and NT-proBNP were added to risk
models of major cardiovascular outcomes. Ranked according
to the strength of prediction, BNP and NT-proBNP were the
primary predictive variables in all outcomes examined, except
Table 4. Discriminatory Changes in Best Risk Models With and Without BNP and NT-proBNP
C Statistics in Each Model (n=5525)
Base Model BNP/NT-proBNP in Model NRI IDI
Death (397 events)
BNP 0.77 (74–0.79) 0.82 (0.80–0.84)* 30.6% (25.2–36.8)* 5.0% (3.5–7.2)*
NT-proBNP 0.81 (0.79–0.83)* 24.3% (17.4–29.3)* 3.3% (2.1–5.0)*
Cardiovascular death (286 events)
BNP 0.77 (0.74–0.80) 0.83 (0.81–0.86)* 36.0% (27.4–41.4)* 5.6% (3.4–8.6)*
NT-proBNP 0.83 (0.80–0.86)* 30.9% (21.7–36.9)* 4.0% (2.4–6.3)*
MI (473 events)
BNP 0.71 (0.68–0.73) 0.72 (0.70–0.75)* 14.3% (9.3–19.5)* 1.2% (0.6–2.1)*
NT-proBNP 0.72 (0.67–0.74)* 10.6% (5.7–16.6)* 0.8% (0.3–1.6)*
HF (221 events)
BNP 0.84 (0.81–0.86) 0.87 (0.85–0.89)* 35.4% (24.7–40.6)* 5.0% (3.0–7.6)*
NT-proBNP 0.87 (0.84–0.89)* 29.9% (21.8–36.6)* 3.8% (2.2–5.8)*
Stroke (115 events)
BNP 0.74 (0.70–0.79) 0.76 (0.72–0.80) 19.3% (8.8–29.9)* 0.4% (0–1.2)
NT-proBNP 0.76 (0.72–0.80) 17.2% (6.3–28.1)* 0.2% (0–0.8)
NRI and IDI summarized as mean percent improvement 95% CI. BNP indicates B-type natriuretic peptide; HF, heart failure; IDI, Integrated Discrimination Index; MI, myocardial infarction;
NRI, Net Reclassiﬁcation Index; NT-proBNP, N-terminal prohormone B-type natriuretic peptide.
*P<0.05, comparison between base model and BNP/NT-proBNP model.
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MI, where they were the second most predictive variable. The
predictive strength of BNP and NT-proBNP was also evident
when viewing the v2 values, which were magnitudes higher
than other signiﬁcant variables in death, cardiovascular death
and HF, moderately higher in stroke, and comparable to
having had a prior MI in outcome of MI. This was also mirrored
in the ability of BNP and NT-proBNP to predict causes of
death, where a signiﬁcant predictive contribution of BNP and
NT-proBNP was present when added to risk models in
outcome of sudden death and HF death, whereas none was
found for fatal MI. The cut-off point that most signiﬁcantly
divided patients into a higher versus lower risk group of
subsequent HF hospitalization was 500 and 700 pg/mL for
BNP and NT-proBNP, in multivariate analysis.
Natriuretic peptides are primarily recognized as predictors
of mortality and HF hospitalization, whereas our ﬁnding of a
strong predictive ability of natriuretic peptide levels in
outcomes of MI and stroke is less validated, especially in
ACS patients. This ability could be attributed to higher levels
of natriuretic peptides in patients with asymptomatic myocar-
dial ischemia15,16 and paroxysmal atrial ﬁbrillation,17,18 which
could predispose to both MI and stroke.
Our risk models also identiﬁed other important predictors
apart from BNP and NT-proBNP. Risk models in other diabetic
populations (TREAT [Trial to Reduce Cardiovascular Events
with Aranesp (darbepoetin-alfa) Therapy]),26 UKPDS [UK
Prospective Diabetes Study]27) have yielded results that also
highlight the importance of the risk factors we identiﬁed, such
as prior HF, glycated hemoglobin, age, heart rate, albuminuria,
and cardiac arrhythmias.28,29 Important differences were that
these studies either used composite end points28 or only
single outcomes29 when examining predictors. Furthermore,
the diabetic patients on which these risk models were based
were either at higher risk (TREAT: 81.1 deaths per 1000 PY)
or lower risk of death (UKPDS: 18.9 deaths per 1000 PY) than
in the present study (32.3 deaths per 1000 PY). Nonetheless,
traditional cardiovascular risk factors combined with markers
of chronic dysglycemia seem to persist as predictors of
adverse cardiovascular events despite the differences in the
diabetic populations studied.
When BNP or NT-proBNP was used to predict death or
cardiovascular death alone compared to using all variables
available excluding these natriuretic peptides, estimates of C
statistics were comparable, but the stand-alone natriuretic
peptide receiver operating characteristic area under the curve
values exceeded those reported earlier in patients with HF or
coronary artery disease.19,30 Thus, a single measurement of
BNP or NT-proBNP contains the same predictive information
about risk of death as all other variables listed in Table 1. Of
note, the reverse was seen in cardiovascular morbidity
Figure. The association of BNP and NT-proBNP concentrations and risk of all-cause death. The hazard of
death is depicted with 95% CIs. The reference of hazard ratio=1.0 corresponds to a BNP concentration of
35 pg/mL, and a NT-proBNP concentration of 125 pg/mL. BNP indicates B-type natriuretic peptide; NT-
proBNP, N-terminal prohormone BNP.
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(MI, HF, stroke) where best risk models outperformed a single
BNP or NT-proBNP measurement. As visually depicted in the
ﬁgure, differences in natriuretic peptides conferred 20-fold
changes in risk of death. This large risk gradient enables
easier identiﬁcation of patients at higher versus lower risk and
reinforces the prognostic information contained in BNP and
NT-proBNP levels.
The addition of either natriuretic peptide to best risk
models improved the discriminatory ability signiﬁcantly. This
was evident in the changes in C statistics, NRI, and Integrated
Discrimination Index. C statistics increased 0.01 to 0.06
depending on outcome, which was reﬂected in NRI increases
of 10.6% to 35.4%. These changes make both BNP and NT-
proBNP valuable prognostic determinants that should be
considered in future risk determination in a comparable
population. Furthermore, history of HF did not inﬂuence the
predictive ability of BNP or NT-proBNP across all outcomes,
including MI and stroke.
Having diabetes mellitus seems to inﬂuence levels of
natriuretic peptides in both the absence and presence of
cardiovascular disease,31,32 which potentially could change
the relationship between levels of natriuretic peptides and risk
of cardiovascular events. Whether natriuretic peptides predict
outcomes differently in ACS patients with type 2 diabetes
mellitus compared to similar patients without diabetes
mellitus is not known. The stand-alone discriminatory strength
of BNP and NT-proBNP in cardiovascular death was somewhat
lower (receiver operating characteristic area under the curve:
BNP 0.58; NT-proBNP 0.68) in patients with coronary artery
disease from the Prevention of Events With Angiotensin
Converting Enzyme (PEACE) trial (16% patients had diabetes
mellitus). In comparison, when BNP was sampled 2 to 4 days
after the infarct in STEMI patients included in the Enoxaparin
Tenecteplase-Tissue-Type Plasminogen Activator With or
Without Glycoprotein IIb/IIIa Inhibitor as Reperfusion Strategy
in ST-Segment Elevation Myocardial Infarction-Thrombolysis In
Myocardial Infarction-23 (ENTIRE-TIMI-23) trial (13% patients
had diabetes mellitus), the receiver operating characteristic
area under the curve for death after 30 days was 0.81,11
which is comparable to our results (area under the
curve30 days: 0.88). This could suggest that the severity of
the coronary pathology inﬂuences the predictive strength of
natriuretic peptides and/or the timing of the sample used for
risk determination is important, as shown by Lindahl et al.33
Earlier studies have shown that levels of natriuretic peptides
are dynamic in the subacute phase following an MI,34 and
smaller studies suggest that patients are at higher risk of
death and left ventricular remodeling if natriuretic peptides
continue to be elevated after the MI, compared with those with
decreasing levels.35,36 In our study, patients were randomized
within 180 days from their ACS. The timing of the baseline
sample in relation to their index ACS did not affect the risk
estimates of BNP or NT-proBNP, nor did the type of index
event (STEMI, NSTEMI, or UAP). This suggests that the
predictive value of natriuretic peptides is retained from shortly
after the event until at least 6 months after the ACS in
patients with type 2 diabetes mellitus, irrespective of coronary
pathology.
As the availability of BNP and NT-proBNP analyses differs
between institutions and regions, we also assessed the
predictive value of BNP compared to NT-proBNP. In the PEACE
trial, BNP was only a predictor of HF, while NT-proBNP was a
predictor of cardiovascular death, HF, and stroke in coronary
artery disease patients.19 Neither biomarker predicted MI. In
the Valsartan Heart Failure Trial (Val-Heft), NT-proBNP proved
superior to BNP in predicting a composite of morbidity and
mortality and HF hospitalization in chronic HF patients;
however, the incremental discriminatory value of NT-proBNP
versus BNP was small.30 In our study of ACS patients with type
2 diabetes mellitus, both natriuretic peptides had comparable
predictive strength in all outcomes studied (death, cardiovas-
cular death, MI, HF, and stroke), albeit NRI and Integrated
Discrimination Index values increased slightly more with BNP
across all outcomes.
Our results expand knowledge of earlier ﬁndings of
enhanced risk prediction using natriuretic peptides in patients
with a recent ACS3,10–12 to also include patients with a recent
ACS and type 2 diabetes mellitus. This prevalent population
has only marginally been studied in this context.37–40 The use
of BNP or NT-proBNP for risk prediction in all ACS patients,
irrespective of diabetes mellitus status, is now further
substantiated. Whether drugs that directly inﬂuence natri-
uretic peptide concentrations (eg, sacubitril41) can modify the
incidence of the cardiovascular outcomes examined in this
study remains speculative.
Limitations
To learn more about how diabetes mellitus per se affects the
predictive ability of natriuretic peptides, a similar study design
with ACS patients with and without type 2 diabetes mellitus
would have been optimal. Furthermore, our average follow-up
time of 2 years precludes any estimates on the long-term
predictive ability of BNP and NT-proBNP. Data on the severity
of the index ACS were not obtained (eg, troponin), which as a
marker of myocardial damage could have attenuated the
prognostic ability of BNP/NT-proBNP. Extrapolating from the
present study to other ACS patients with type 2 diabetes
mellitus should be done cautiously, as inclusion criteria may
have led to selection bias compared to patients not included
in this trial. Importantly, patients with estimated glomerular
ﬁltration rate <30 mL/min per 1.73 m2 were excluded from
this study, and renal function is shown to affect levels of
natriuretic peptides.42
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Conclusion
In a population of patients with a recent ACS and type 2
diabetes mellitus, BNP and NT-proBNP are important and
comparable predictors of death, cardiovascular death, MI, HF,
as well as stroke. Both natriuretic peptides improve the
discriminatory ability signiﬁcantly when added to best risk
models with known predictors of adverse cardiovascular
outcomes, irrespective of prior history of HF or prior
cardiovascular disease.
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Table S1. Characteristics of all included patients grouped according to quartiles of BNP 
 BNP (5-49 pg/ml) BNP (50-105 pg/ml) BNP (106-218 pg/ml) BNP (218-4231 pg/ml)  
 n=1381 n=1383 n=1378 n=1383 
P 
value 
      
randomized to lixisenatide          666    (48.2%) 745    (53.9%) 696    (50.5%) 669    (48.4%) 0.009  
age (yrs) 56.7 ± 9.3 59.5 ± 9.1 61.3 ± 9.2 63.5 ± 9.7 <0.001  
male (%)             1019    (73.8%) 968    (70.0%) 982    (71.3%) 896    (64.8%) <0.001  
BMI (kg/m2) 30.8 ± 5.7 30.3 ± 5.8 29.9 ± 5.6 29.3 ± 5.6 <0.001  
Race     0.020  
Asian 204    (14.8%) 186    (13.4%) 183    (13.3%) 157    (11.4%)  
Black 57     (4.1%) 44     (3.2%) 33     (2.4%) 55     (4.0%)  
Other 102    (7.4%) 115    (8.3%) 117    (8.5%) 137    (9.9%)  
White 1018    (73.7%) 1038    (75.1%) 1045    (75.8%) 1034    (74.8%)  
ethnicity – hispanic 375    (27.2%) 407    (29.4%) 413    (30.0%) 451    (32.6%) 0.019  
Region     <0.001  
Africa/Near East 86     (6.2%) 71     (5.1%) 58     (4.2%) 54     (3.9%)  
Asia Pacific 184    (13.3%) 175    (12.7%) 172    (12.5%) 138    (10.0%)  
Eastern Europe 290    (21.0%) 332    (24.0%) 377    (27.4%) 414    (29.9%)  
North America 219    (15.9%) 181    (13.1%) 181    (13.1%) 135    (9.8%)  
South and Centr. America 421    (30.5%) 438    (31.7%) 449    (32.6%) 516    (37.3%)  
Western Europe 181    (13.1%) 186    (13.4%) 141    (10.2%) 126    (9.1%)  
Systolic blood pressure (mmHg) 128.4 ± 15.1 129.9 ± 17.0 130.0 ± 17.8 129.9 ± 19.3 0.035  
Diastolic blood pressure (mmHg) 78.0 ± 9.2 77.0 ± 9.6 77.2 ± 10.5 76.5 ± 10.8 0.003  
heart rate (bpm) 70.5 ± 9.9 69.0 ± 10.3 69.5 ± 10.5 71.3 ± 10.9 <0.001  
current smoker         194    (14.0%) 174    (12.6%) 134    (9.7%) 125    (9.0%) <0.001  
former smoker 656    (47.5%) 614    (44.4%) 640    (46.4%) 612    (44.3%) 0.24  
Medical history      
MI             252    (18.2%) 299    (21.6%) 314    (22.8%) 393    (28.4%) <0.001  
HF             172    (12.5%) 245    (17.7%) 304    (22.1%) 514    (37.2%) <0.001  
atrial fibrillation/flutter            30     (2.2%) 63     (4.6%) 96     (7.0%) 172    (12.4%) <0.001  
PAD 65     (4.7%) 86     (6.2%) 111    (8.1%) 151    (10.9%) <0.001  
TIA            29     (2.1%) 33     (2.4%) 23     (1.7%) 42     (3.0%) 0.11  
ventricular tachycardia         13     (0.9%) 14     (1.0%) 21     (1.5%) 26     (1.9%) 0.10  
stroke       45     (3.3%) 68     (4.9%) 67     (4.9%) 112    (8.1%) <0.001  
CABG          51     (3.7%) 101    (7.3%) 157    (11.4%) 151    (10.9%) <0.001  
implanted pacemaker             17     (1.2%) 23     (1.7%) 43     (3.1%) 60     (4.3%) <0.001  
carotid disease  28     (2.0%) 28     (2.0%) 39     (2.8%) 44     (3.2%) 0.12  
hypertension      1001    (72.5%) 1068    (77.2%) 1062    (77.1%) 1079    (78.0%) 0.002  
Index event     <0.001  
STEMI 458    (33.2%) 591    (42.7%) 684    (49.6%) 710    (51.3%)  
NSTEMI 591    (42.8%) 559    (40.4%) 505    (36.6%) 479    (34.6%)  
UAP 332    (24.0%) 233    (16.8%) 189    (13.7%) 194    (14.0%)  
PCI treatment at index ACS    903    (65.4%) 906    (65.5%) 870    (63.1%) 727    (52.6%) <0.001  
insulin-treated          463    (33.5%) 539    (39.0%) 555    (40.3%) 602    (43.5%) <0.001  
duration of diabetes (yrs) 7.8 ± 7.2 9.2 ± 8.2 9.4 ± 8.3 10.7 ± 9.0 <0.001  
retinopathy 122    (8.8%) 134    (9.7%) 141    (10.2%) 194    (14.0%) <0.001  
neuropathy           215    (15.6%) 224    (16.2%) 209    (15.2%) 271    (19.6%) 0.007  
asthma           33     (2.4%) 53     (3.8%) 36     (2.6%) 32     (2.3%) 0.05  
COPD          42     (3.0%) 59     (4.3%) 79     (5.7%) 69     (5.0%) 0.005  
HbA1c (%) 7.7 ± 1.3 7.7 ± 1.3 7.7 ± 1.3 7.7 ± 1.2 0.64  
HDL(mg/dl) 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 0.58  
LDL (mg/dl) 2.1 ± 0.9 2.0 ± 1.0 2.0 ± 0.9 2.0 ± 0.9 0.17  
eGFR (ml/min/1.73m2) 82.6 ± 20.4 78.6 ± 20.8 74.4 ± 21.0 68.1 ± 20.2 <0.001  
Albuminuria     <0.001  
normoalbuminuria 1134    (82.1%) 1074    (77.7%) 1019    (73.9%) 875    (63.3%)  
microalbuminura 200    (14.5%) 249    (18.0%) 269    (19.5%) 345    (24.9%)  
macroalbuminuria 47     (3.4%) 60     (4.3%) 90     (6.5%) 163    (11.8%)  
Hemoglobin (g/dL) 14.1 ± 1.4 13.9 ± 1.3 13.8 ± 1.4 13.3 ± 1.5 <0.001  
Na (mmol/l) 140.2 ± 2.7 140.3 ± 2.8 140.5 ± 3.0 140.5 ± 3.2 0.033  
albumin (g/dl) 41.6 ± 3.2 40.9 ± 3.1 40.4 ± 3.5 39.3 ± 4.0 <0.001 
CRP (mg/dl)  1.9 (1.8-2.0) 1.9 (1.8-2.0) 2.1 (2.0-2.3) 2.4 (2.3-2.6) <0.001 
BNP (pg/ml) 28 (27-28) 73 (72-74) 150 (148-152) 431 (419-443)  
NT-proBNP (pg/ml) 78 (74-81) 208 (200-215) 470 (453-487) 1541 (1468-1618)  
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Table S2. Linear regression of BNP and NT-proBNP with all variables listed in the model 
 BNP P value NT-proBNP P value 
     
randomized to lixisenatide          0.0 (-14.0, 14.0) 0.996 16.2 (-66.4, 98.8) 0.701 
age (yrs) 1.9 (1.0, 2.9) <0.001 7.2 (1.6, 12.8) 0.012 
male (%)             15.0 (-3.6, 33.6) 0.113 8.2 (-101.4, 117.9) 0.883 
BMI (kg/m2) -7.0 (-8.4, -5.6) <0.001 -46.8 (-55.2, -38.4) <0.001 
Race     
Black vs. white 19.4 (-20.4, 59.2) 0.340 27.7 (-207.3, 262.8) 0.817 
Asian vs. white -37.9 (-64.6, -11.2) 0.005 -225.1 (-382.7, -67.4) 0.005 
other vs. white -1.0 (-27.3, 25.4) 0.943 127.4 (-28.3, 283.2) 0.109 
ethnicity – hispanic 19.8 (0.7, 38.9) 0.042 169.9 (57.0, 282.8) 0.003 
Systolic blood pressure (mmHg) -1.0 (-1.6, -0.5) <0.001 -5.3 (-8.6, -2.0) 0.002 
Diastolic blood pressure (mmHg) 1.3 (0.4, 2.2) 0.007 6.6 (1.1, 12.2) 0.019 
heart rate (bpm) 2.1 (1.4, 2.8) <0.001 13.8 (9.7, 18.0) <0.001 
current smoker         -5.0 (-29.9, 19.8) 0.692 -78.0 (-224.8, 68.8) 0.298 
former smoker 3.0 (-13.0, 18.9) 0.717 -31.9 (-126.2, 62.5) 0.508 
Medical history     
MI             28.5 (10.4, 46.5) 0.002 35.3 (-71.3, 141.9) 0.516 
HF             114.2 (95.7, 132.7) <0.001 648.8 (539.4, 758.2) <0.001 
atrial fibrillation/flutter            34.2 (4.4., 64.0) 0.024 232.8 (57.0, 408.7) 0.009 
PAD 27.7 (-0.5, 56.0) 0.054 290.0 (123.2, 456.7) 0.001 
TIA            2.5(-44.8, 49.9) 0.916 -48.3 (-327.7, 231.2) 0.735 
ventricular tachycardia         82.3 (20.9, 143.6) 0.009 182.8 (-179.4, 545.0) 0.323 
stroke       42.7 (10.6, 74.7) 0.009 105.2 (-84.0, 294.4) 0.276 
CABG          -5.0 (-32.3, 22.4) 0.722 -166.9 (-328.3, -5.5) 0.043 
implanted pacemaker             6.5 (-39.1, 52.1) 0.781 -20.6 (-289.9, 248.8) 0.881 
carotid disease  -28.1 (-74.8, 18.6) 0.239 -120.8 (-396.6, 154.9) 0.390 
hypertension      -20.6 (-38.8, -2.3) 0.027 -95.5 (-203.4, 12.4) 0.083 
Index event     
STEMI 103.0 (81.2, 124.8) <0.001 579.6 (451.0, 708.3) <0.001 
NSTEMI 50.0 (28.8, 71.2) <0.001 294.5 (169.3, 419.6) <0.001 
PCI treatment at index ACS    -41.0 (-56.7, -25.3) <0.001 -179.6 (-272.2, -86.9) <0.001 
insulin-treated          -12.7 (-29.1, 3.7) 0.130 -17.6 (-114.5, 79.3) 0.722 
duration of diabetes (yrs) -0.1 (-1.1, 1.0) 0.900 -4.6 (-10.7, 1.5) 0.137 
Retinopathy -12.1 (-37.1, 12.9) 0.343 -68.3 (-215.9, 79.2) 0.364 
neuropathy           -19.3 (-40.0, 1.4) 0.068 -12.6 (-135.0, 109.8) 0.840 
asthma           0.8 (-42.7, 44.4) 0.970 -46.0 (-303.1, 211.1) 0.726 
COPD          -2.1 (-32.2, 32.9) 0.905 -67.4 (-274.5, 139.7) 0.523 
HbA1c (%) -3.6 (-9.7, 2.6) 0.254 -51.8 (-88.1, -15.5) 0.005 
HDL(mg/dl) -10.5 (-37.7, 16.7) 0.449 -91.0 (-251.5, 69.5) 0.267 
LDL (mg/dl) 1.4 (7.0, 9.7) 0.750 2.0 (-47.3, 51.2) 0.938 
eGFR (ml/min/1.73m2) -1.8 (-2.1, -1.4) <0.001 -14.4 (-16.7, -12.2) <0.001 
micro vs. Normoalbuminuria 67.3 (48.7, 85.9) <0.001 443.7 (334, 553.4) <0.001 
macro vs. Normoalbuminuria 89.6 (57.6, 121.6) <0.001 661.0 (472.2, 849.9) <0.001 
Hemoglobin (g/dL) -21.4 (-27.4, -15.4) <0.001 -98.3 (-133.6, -63.1) <0.001 
Na (mmol/l) 2.4 (-0.2, 4.9) 0.072 -5.1 (-20.3, 10.0) 0.506 
albumin (g/dl) -13.8 (-16.1, -11.5) <0.001 -85.4 (-99.1, -71.8) <0.001 
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Table S3. Variables independently associated with BNP/NT-proBNP concentrations, and 
corresponding r2 values for regression models with the 5 listed variables 
 1st 2nd 3rd 4th 5th 
      
log2BNP 
(r2=0.20) 
Albumin 
 (χ2:318, coeff:- 0.09)  
Age (per 10 years) 
(χ2:316, coeff: -0.35)  
Prior HF 
 (χ2: 312, coeff: 0.78)  
STEMI 
 (χ2:227, coeff: 0.57)  
BMI (per 5 kg/m2) 
 (χ2:80, coeff: -0.15)  
log2NT-proBNP 
(r2=0.28) 
eGFR 
(χ2:672, coeff: 0.27)  
Albumin 
(χ2:527, coeff: -0.14)  
STEMI 
(χ2: 381, coeff: 0.87)  
BMI (per 5 kg/m2) 
(χ2:305, coeff: -0.34)  
prior HF 
(χ2:262, coeff: 0.86)  
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Table S4. Unadjusted estimates of predictors of outcomes found significant in multivariate models 
using base variables and BNP (n=5525) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome 1st 2nd 3rd 4th 5th 
      
Death 
(397 events ) 
log2BNP 
HR 1.90 (1.78-2.03) 
AF 
HR 2.90 (2.22-3.79) 
NSTEMI  
HR 1.53 (1.26-1.86) 
Na* 
HR 1.10 (1.05-1.16) 
HR per 10 
HR 1.21 (1.11-1.34) 
CV death 
(286 events ) 
log2BNP 
HR 2.01 (1.87-2.17) 
HbA1c 
HR 1.23 (1.13-1.34) 
AF 
HR 3.14 (2.31-4.25) 
NSTEMI 
HR 1.61 (1.28-2.04) 
HR per 10 
HR 1.25 (1.12-1.40) 
MI  
(473 events ) 
prior MI 
HR 2.63 (2.19-3.16) 
log2BNP  
HR 1.33 (1.25-1.41) 
NSTEMI 
HR 1.90 (1.59-2.28) 
prior stroke 
HR 2.50 (1.89-3.33) 
PAD 
HR 2.52 (1.94-3.29) 
HF 
(221 events ) 
log2BNP  
HR 1.96 (1.80-2.14) 
BMI per 5  
HR 1.31 (1.19-1.43) 
HR per 10 
HR 1.34 (1.18-1.51) 
prior HF 
HR 4.16 (3.19-5.42) 
prior MI 
HR 3.09 (2.37-4.03) 
Stroke  
(115 events ) 
log2BNP 
HR 1.49 (1.33-1.68) 
 prior TIA 
HR 4.90 (2.69-8.91) 
macroalbuminuria 
HR 3.05 (1.86-4.99) 
Age per 10 
HR 1.61 (1.32-1.95) 
 LDL per 10 
HR 1.07 (1.02-1.12) 
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Table S5. Unadjusted estimated of predictors of outcomes found significant in multivariate models 
using base variables and NT-proBNP (n=5525) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome 1st 2nd 3rd 4th 5th 
      
Death 
(397 events ) 
log2NT-proBNP 
HR 1.64 (1.56-1.73) 
NSTEMI  
HR 1.53 (1.26-1.86) 
PCI 
HR 0.52 (0.42-0.63) 
DBP# 
HR 1.04 (1.02-1.06) 
Na* 
HR 1.10 (1.05-1.16) 
CV death 
(286 events ) 
log2NT-proBNP 
HR 1.72 (1.62-1.83) 
HbA1c 
HR 1.23 (1.13-1.34) 
NSTEMI 
HR 1.61 (1.28-2.04) 
AF 
HR 3.14 (2.31-4.25) 
prior HF 
HR 2.87 (2.27-3.62) 
MI  
(473 events ) 
prior MI 
HR 2.63 (2.19-3.16) 
log2NT-proBNP 
HR 1.23 (1.18-1.29) 
NSTEMI 
HR 1.90 (1.59-2.28) 
prior stroke 
HR 2.50 (1.89-3.33) 
PAD 
HR 2.52 (1.94-3.29) 
HF 
(221 events ) 
log2NT-proBNP  
HR 1.68 (1.57-1.80) 
BMI per 5 
HR 1.31 (1.19-1.43) 
NSTEMI 
HR 1.91 (1.47-2.49) 
prior HF 
HR 4.16 (3.19-5.42) 
prior MI 
HR 3.09 (2.37-4.03) 
Stroke  
(115 events ) 
log2NT-proBNP 
HR 1.34 (1.22-1.48) 
 prior TIA 
HR 4.90 (2.69-8.91) 
macroalbuminuria 
HR 3.05 (1.86-4.99) 
Age per 10 
HR 1.61 (1.32-1.95) 
 LDL per 10 
HR 1.07 (1.02-1.12) 
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Table S6. Predictors of outcomes ranked according to χ2 value using base variables and BNP and 
stratified according to history of heart failure (No prior HF, n=4290; Prior HF, n=1235)  
Outcome 
 1st 2nd 3rd 
 
 
   
Death 
(397 events ) 
No prior HF 
log2BNP 
(χ2:108, HR 1.68) 
HR per 10 
(χ2:11, HR 1.24) 
Age per 10  
(χ2:9, HR 1.28) 
 
Prior HF 
log2BNP 
(χ2:108, HR 1.72) 
AF 
(χ2:13, HR 1.93) 
Race 
(χ2:13, HR 1.42) 
     
CV death 
(286 events ) 
No prior HF 
log2BNP 
(χ2:101, HR 1.80) 
AF 
(χ2:12, HR 2.45) 
NSTEMI  
(χ2:9, HR 1.64) 
 
Prior HF 
log2BNP 
(χ2:95, HR 1.84) 
CABG 
(χ2:10, HR 2.03) 
PAD  
(χ2:9, HR 1.90) 
     
MI 
(473 events ) 
No prior HF 
log2BNP 
(χ2:29, HR 1.23) 
prior MI 
(χ2:27, HR 1.86) 
PAD 
(χ2:21, HR 2.03) 
 
Prior HF 
log2BNP 
(χ2:26, HR 1.34) 
prior MI 
(χ2:17, HR 2.10) 
NSTEMI 
(χ2:15, HR 2.00) 
     
HF 
(221 events ) 
No prior HF 
log2BNP  
(χ2:52, HR 1.70) 
HR per 10  
(χ2:22, HR 1.53) 
macroalbuminuria 
(χ2:13, HR 2.78) 
 
Prior HF 
log2BNP  
(χ2:100, HR 1.94) 
BMI per 5 
(χ2:28, HR 1.39) 
DBP* 
(χ2:12, HR 1.06) 
     
Stroke 
(115 events ) 
No prior HF 
log2BNP 
(χ2:15, HR 1.40) 
macroalbuminuria 
(χ2:12, HR 2.98) 
TIA 
(χ2:10, HR 3.98) 
 
Prior HF 
log2BNP 
(χ2:8, HR 1.31) 
TIA 
(χ2:6, HR 2.46) 
MI 
(χ2:5, HR 2.20) 
 
Hazard rat io’s reflect 1 unit changes if nothing else is stated. For log2BNP that translates into a doubling of the 
untransformed BNP concentrations. Macroalbuminuria: >300 mg albumin excret ion/24 h. *per 1 mmHg decrease below 
≥75 mmHg.. AF- atrial fibrillation/flutter. NSTEMI – non-ST elevation myocardial infarction at index event. HR – 
heart rate. PAD – peripheral artery disease. TIA – transient ischemic attack. Duration of T2D is per year since 
diagnosis. All variables are significant, p<0.05. 
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Table S7. Discriminatory changes in best risk models with and without BNP stratified according to 
history of heart failure (No prior HF, n=4290; Prior HF, n=1235) 
 
C statistics in each model (n=5525) 
 
*p<0.05, comparison between base model and BNP model. #p=0.053, comparison between base model and BNP 
model.  NRI – Net Reclassification Index. IDI – Integrated Discrimination Index. NRI and IDI summarized as mean 
percent improvement ±95%CI.. 
  
  
Base model BNP in model NRI IDI 
Death No prior HF 0.77 (0.73-0.80) 0.80 (0.77-0.84)* 25.7% (17.3-34.7)* 4.0% (2.4-6.8)* 
(397 events) Prior HF 0.69 (0.64-0.73) 0.78 (0.75-0.81)* 38.5% (28.7-45.4)* 7.8% (4.4-11.4)* 
      
CV death No prior HF 0.76 (0.72-0.80) 0.81 (0.77-0.85)* 27.4% (17.7-35.6)* 3.7% (1.9-6.8)* 
(286 events) Prior HF 0.73 (0.68-0.77) 0.82 (0.79-0.85)* 39.6% (28.6-51.1)* 6.9% (3.6-11.6)* 
      
MI No prior HF 0.72 (0.69-0.75) 0.73 (0.70-0.75)# 13.7% (5.6-19.4)* 0.8% (0.2-1.9)* 
(473 events) Prior HF 0.71 (0.66-0.76) 0.73 (0.68-0.77) 21.7% (8.4-30.9)* 2.4% (0.9-4.7)* 
      
HF No prior HF 0.83 (0.79-0.87) 0.86 (0.83-0.90)* 29.4% (15.3-39.4)* 3.4% (1.4-6.7)* 
(221 events) Prior HF 0.75 (0.71-0.80) 0.81 (0.77-0.85)* 38.8% (26.6-46.6)* 9.0% (5.1-13.3)* 
      
Stroke No prior HF 0.76 (0.71-0.82) 0.79 (0.73-0.84) 17.6% (1.8-31.1)* 0.1% (-0.6-1.6) 
(115 events) Prior HF 0.67 (0.58-0.75) 0.69 (0.61-0.76) 21.3% (0.0-35.2)* 1.0% (0.1-3.9)* 
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 Table S8. Discriminatory changes in best risk models without BNP compared to BNP alone, in all 
patients (n=5525) and stratified according to history of heart failure (No prior HF, n=4290; Prior 
HF, n=1235). 
 
*p<0.05, significant difference between base model compared to BNP model. 
 
 
 
 
 
 
 
 
 
 
All patients No prior HF Prior HF 
Outcome Base model BNP Base model BNP 
Base 
model BNP 
       
Death 
(397 events ) 0.77 (0.74-0.79) 0.77 (0.75-0.80) 0.77 (0.74-80) 0.75 (0.71-0.78) 0.71 (0.67-0.74) 0.76 (0.73-0.80)* 
CV death 
(286 events ) 0.77 (0.74-0.80) 0.79 (0.76-0.82) 0.76 (0.72-0.80) 0.76 (0.72-0.81) 0.73 (0.68-0.77) 0.78 (0.74-0.82) 
MI  
(473 events ) 0.71 (0.68-0.73) 0.63 (0.61-0.66)* 0.72 (0.69-0.75) 0.62 (0.59-0.65)* 0.71 (0.66-0.76) 0.66 (0.61-0.70) 
HF 
(221 events ) 0.84 (0.81-0.86) 0.78 (0.75-0.81)* 0.83 (0.79-0.87) 0.76 (0.72-0.80)* 0.75 (0.71-0.80) 0.74 (0.69-0.78) 
Stroke  
(115 events ) 0.75 (0.70-0.79) 0.67 (0.62-0.72)* 0.76 (0.71-0.82) 0.67 (0.60-0.74)* 0.67 (0.58-0.75) 0.61 (0.52-0.70) 
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 Table S9. Predictors of outcomes ranked according to χ2 value using base variables and BNP in 
patients without prior CV disease (n=2899) 
Outcome 1st 2nd 3rd 
    
Death 
(112 events ) 
log2BNP 
(χ2:81, HR 1.78) 
DBP* 
(χ2:14, HR 1.05) 
Na#  
(χ2:7, HR 0.84) 
CV death 
(74 events ) 
log2BNP 
(χ2:81, HR 2.04) 
DBP* 
(χ2:16, HR 1.06) 
duration of T2D 
(χ2:10, HR 1.04) 
MI  
(153 events ) 
log2BNP 
(χ2:18, HR 1.27) 
macroalbuminuria  
(χ2:12, HR 2.34) 
hypertension 
(χ2:10, HR 1.89) 
HF 
(39 events ) 
log2BNP  
(χ2:31, HR 1.87) 
duration of T2D 
(χ2:13, HR 1.06) 
albumin 
(χ2:6, HR 0.91) 
Stroke  
(31 events ) 
carotid disease 
(χ2:41, HR 34.79) 
 microalbuminuria 
(χ2:16, HR 5.08) 
DBP* 
(χ2:16, HR 1.09) 
Hazard rat io’s reflect 1 unit changes if nothing else is stated. For log2BNP that translates into a doubling of the 
untransformed BNP concentrations. Microalbuminuria ≥30-300 mg albumin excretion/24h. Macroalbuminuria: >300 
mg albumin excret ion/24h.. *per 1 mmHg decrease below ≥75 mmHg.. T2D – Type 2 diabetes (years). All variables are 
significant, p<0.05. 
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Table S10. Predictors of outcomes ranked according to χ2 value using base variables and NT-
proBNP in patients without prior CV disease (n=2899) 
Outcome 1st 2nd 3rd 
    
Death 
(112 events ) 
log2proBNP 
(χ2:81, HR 1.61) 
DBP* 
(χ2:16, HR 1.05) 
age per 10 
(χ2:8, HR 1.36) 
CV death 
(74 events ) 
log2proBNP 
(χ2:81, HR 1.81) 
DBP* 
(χ2:16, HR 1.06) 
duration of T2D 
(χ2:10, HR 1.04) 
MI  
(153 events ) 
log2proBNP 
(χ2:18, HR 1.21) 
macroalbuminuria 
(χ2:11, HR 2.23) 
hypertension 
(χ2:10, HR 1.92) 
HF 
(39 events ) 
log2proBNP  
(χ2:53, HR 1.91) 
duration of T2D 
(χ2:14, HR 1.06) 
NSTEMI 
(χ2:5, HR 2.06) 
Stroke  
(31 events ) 
carotid disease 
(χ2:37, HR 29.09) 
 microalbuminuria 
(χ2:16, HR 5.06) 
DBP* 
(χ2:15, HR 1.08) 
 
Hazard rat io’s reflect 1 unit changes if nothing else is stated. For log2BNP that translates into a doubling of the 
untransformed BNP concentrations. Microalbuminuria ≥30-300 mg albumin excretion/24h. Macroalbuminuria: >300 
mg albumin excret ion/24h. DBP* d iastolic blood pressure per 1 mmHg decrease below ≥75 mmHg. NSTEMI – non-ST 
elevation myocardial infarction at index event. T2D – Type 2 diabetes (years). All variables are significant, p<0.05. 
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Table S11. Predictors of outcomes ranked according to χ2 value using base variables and BNP with 
and without adding information on LVEF (n=3390) 
 
Outcome 
 1st 2nd 3rd 
 
 
   
Death 
(236 events ) 
Variables 
log2BNP 
(χ2:99, HR 1.60) 
Duration of T2D 
(χ2:17, HR 1.03) 
male 
(χ2:9, HR 1.59) 
 
Variables 
+LVEF 
log2BNP 
(χ2:108, HR 1.60) 
Duration of T2D 
(χ2:17, HR 1.03) 
male 
(χ2:9, HR 1.59) 
     
CV death 
(166 events ) 
Variables 
log2BNP 
(χ2:131, HR 1.86) 
HbA1c 
(χ2:10, HR 1.22) 
Duration of T2D  
(χ2:10, HR 1.03) 
 
Variables 
+LVEF 
log2BNP 
(χ2:95, HR 1.79) 
HbA1c 
(χ2:11, HR 1.23) 
Duration of T2D  
(χ2:10, HR 1.03) 
     
MI 
(290 events ) 
Variables 
prior MI 
 (χ2:43, HR 2.21) 
NSTEMI 
 (χ2:24, HR 1.81) 
log2BNP 
 (χ2:23, HR 1.21) 
 
Variables 
+LVEF 
prior MI 
 (χ2:43, HR 2.21) 
NSTEMI 
 (χ2:24, HR 1.81) 
log2BNP 
 (χ2:23, HR 1.21) 
     
HF 
(148 events ) 
Variables 
log2BNP  
(χ2:97, HR 1.80) 
BMI per 5  
(χ2:25, HR 1.33) 
HR per 10 
(χ2:20, HR 1.43) 
 
Variables 
+LVEF 
log2BNP  
(χ2:97, HR 1.80) 
BMI per 5  
(χ2:25, HR 1.33) 
HR per 10 
(χ2:20, HR 1.43) 
     
Stroke 
(70 events ) 
Variables 
log2BNP 
(χ2:21, HR 1.42) 
TIA 
(χ2:11, HR 3.59) 
LDL per 10 
(χ2:7, HR 1.08) 
 
Variables  
+LVEF 
log2BNP 
(χ2:21, HR 1.42) 
TIA 
(χ2:11, HR 3.59) 
LDL per 10 
(χ2:7, HR 1.08) 
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Table S12. Predictors of outcomes ranked according to χ2 value using base variables and NT-
proBNP with and without adding information on LVEF at index ACS (n=3390) 
 
Outcome 
 1st 2nd 3rd 
 
 
   
Death 
(236 events ) 
Variables 
log2NT-proBNP 
(χ2:107, HR 1.46) 
COPD 
(χ2:9, HR 1.81) 
Male 
(χ2:9, HR 1.58) 
 
Variables 
+LVEF 
log2NT-proBNP 
 (χ2:107, HR 1.46) 
COPD 
(χ2:9, HR 1.81) 
Male 
(χ2:9, HR 1.58) 
     
CV death 
(166 events ) 
Variables 
log2NT-proBNP 
 (χ2:115, HR 1.57) 
HbA1c 
(χ2:14, HR 1.27) 
Male 
(χ2:9, HR 1.71) 
 
Variables  
+LVEF 
log2NT-proBNP 
 (χ2:68, HR 1.49) 
HbA1c 
(χ2:13, HR 1.26) 
AF 
(χ2:10, HR 1.92) 
     
MI 
(290 events ) 
Variables 
prior MI 
 (χ2:44, HR 2.24) 
log2NT-proBNP 
 (χ2:30, HR 1.18) 
NSTEMI 
 (χ2:25, HR 1.18) 
 
Variables 
+LVEF 
prior MI 
 (χ2:44, HR 2.24) 
log2NT-proBNP 
 (χ2:30, HR 1.18) 
NSTEMI 
 (χ2:25, HR 1.18) 
     
HF 
(148 events ) 
Variables 
log2NT-proBNP  
(χ2:86, HR 1.56) 
BMI per 5  
(χ2:25, HR 1.33) 
CABG 
(χ2:19, HR 2.48) 
 
Variables 
+LVEF 
log2NT-proBNP  
(χ2:86, HR 1.56) 
BMI per 5  
(χ2:25, HR 1.33) 
CABG 
(χ2:19, HR 2.48) 
     
Stroke 
(70 events ) 
Variables 
log2NT-proBNP  
 (χ2:14, HR 1.26) 
TIA 
(χ2:10, HR 3.36) 
LDL per 10 
(χ2:6, HR 1.07) 
 
Variables 
+LVEF 
log2NT-proBNP  
 (χ2:14, HR 1.26) 
TIA 
(χ2:10, HR 3.36) 
LDL per 10 
(χ2:6, HR 1.07) 
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Table S13. Discriminatory changes in best risk models with and without BNP and NT-proBNP with 
LVEF and coronary intervention procedure added to base model 
 
C statistics in each model (n=3390) 
 
*p<0.05, comparison between base model and /NT-proBNP model. NRI – Net Reclassification Index. IDI – Integrated 
Discrimination Index. NRI and IDI summarized as mean percent improvement ±95%CI. 
 
 
 
 
 
 
  
Base model 
BNP/ 
NT-proBNP in 
model 
NRI IDI 
Death BNP 0.75 (0.72-0.78) 0.79 (0.76-0.82)* 31.8% (25.1-37.4)* 5.3% (3.5-7.4)* 
(236 events) NT-proBNP  0.79 (0.75-0.82)* 25.5% (19.4-31.9)* 3.5% (2.3-5.1)* 
      
CV death BNP 0.77 (0.73-0.81) 0.83 (0.80-0.86)* 34.8% (28.0-41.7)* 5.7% (3.7-8.4)* 
(166 events) NT-proBNP  0.82 (0.79-0.85)* 29.9% (22.4-36.8)* 3.9% (2.3-6.2)* 
      
MI BNP 0.70 (0.67-0.73) 0.71 (0.67-0.74) 14.3% (9.3-19.5)* 1.2% (0.6-2.1)* 
(290 events) NT-proBNP  0.71 (0.68-0.74) 10.6% (5.7-16.6)* 0.8% (0.3-1.6)* 
      
HF BNP 0.86 (0.83-0.89) 0.88 (0.85-0.90)* 35.4% (24.7-40.6)* 5.0% (3.0-7.6)* 
(148 events) NT-proBNP  0.88 (0.85-0.90)* 29.9% (21.8-36.6)* 3.8% (2.2-5.8)* 
      
Stroke BNP 0.72 (0.66-0.78) 0.76 (0.70-0.82) 19.3% (8.8-29.9)* 0.4% (0-1.2) 
(70 events) NT-proBNP  0.75 (0.70-0.81) 17.2% (6.3-28.1)* 0.2% (0-0.8) 
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Myocardial infarction summary criteria for positive adjudication: 
 
Spontaneous MI: Elevated cardiac markers (CM) and either new electrocardiographic (ECG) 
changes or a clinical presentation consistent with an acute MI. 
○PCI-related MI: Elevated CM (or other criteria in the absence of elevated CM). 
○Coronary artery bypass graft (CABG)–related MI: Elevated CM and new ECG changes (or other 
criteria). 
Detailed criteria for positive adjudication: 
a. Spontaneous MI: 
Cardiac markers: 
○Troponinp>upper limit of normal (ULN) or 
○CK-MB>ULN  
 
and at least 1 of the following: 
○Ischemic symptoms: rest or accelerated symptoms (pain, dyspnea, and pressure) consistent with 
myocardial ischemia. 
○ECG changes consistent with infarction: 
•New significant Q waves (or R waves in V1-V2)in 2 contiguous leads in absence of previous left 
ventricular hypertrophy or conduction abnormalities. OR 
•Evolving ST-segment to T-wave changes in≥2 contiguous leads. 
•Development of new left bundle-branch block. 
•ST-segment elevation requiring thrombolytics or PCI. 
b. PCI-related MI: 
Cardiac markersq: 
1. Assuming baseline value>ULN 
2. Within 48 hours of procedure 
a. Troponinp>3× ULN OR 
b. CK-MB>3× ULN 
c. CABG-related MI:  
Cardiac markers: 
1. Assuming baseline value>ULN 
2. Within 72 hours of procedure 
a. Troponinp>5× ULN OR 
b. CK-MB>5× ULN 
AND 
c. New pathologic Q waves or left bundle-branch block, new native or graft vessel occlusion, or 
imaging evidence of loss of viable myocardium. 
3. Hospitalization for UA 
a. Unplanned hospitalization for worsening angina defined as rest or accelerated symptoms (pain, 
dyspnea, and pressure) consistent with myocardialischemia AND 
b. Cardiac markers (CK-MB or troponin) suggestive of myocardial injury but not meeting MI 
criteria. Note: if abnormal troponin, value must be in the suggestive (middle) range and below the 
threshold for MI. 
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Baseline variables used in risk models: 
Log2BNP, Log2NT-proBNP 
Race, ethnicity, region, randomization to lixisenatide, PCI at index ACS, age, gender, BMI, systolic 
blood pressure, diastolic blood pressure (above/below 70 mmHg), heart rate, smoking 
(current/never/former), history of MI, history of HF, history of AF, history of PAD, history of TIA, 
history of stroke, history of ventr. tachycardia, history of CABG, pacemaker implanted, carotid 
disease, history of hypertension, index ACS (STEMI, NSTEMI, UAP), insulin use (yes/no), 
duration of T2D, retinopathy, neuropathy, asthma, COPD, albuminuria (no/micro/macro), logCRP, 
HbA1c, HDL, LDL, eGFR, Hgb, Na (above/below 140 mmol/L), albumin. 
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Figure S1. The association of BNP concentrations and risk of all-cause death according to history of 
heart failure 
 
The hazard of death is depicted with 95%CI. The Cox spline model was fully adjusted for all significant variables. The 
reference of HR=1.0 corresponds to a BNP concentration of 35 pg/ml. 
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